FIELD: medicine, cardiology. SUBSTANCE: infusion solution contains: taurine, 5.500-11.000; potassium asparaginate, 0.997-11.244; magnesium asparaginate, 0.701-0.873; sorbitol, 1.000-5.000; and water for injections, up to 100%. EFFECT: higher level and wider range of specific activity at simultaneous decrease or elimination of side effects. 3 ex, 3 tbl
Title | Year | Author | Number |
---|---|---|---|
AGENT FOR TREATMENT OF PATIENTS WITH CARDIOVASCULAR DISEASES | 1999 |
|
RU2168989C1 |
METHOD TO OBTAIN INJECTION PREPARATION BASED UPON A SUBSTANCE OF P-VITAMIN ACTIVITY | 2001 |
|
RU2181051C1 |
MEDICINAL AGENT "ASPARKAM-1" FOR REGULATION OF METABOLIC PROCESSES AND METHOD FOR ITS PREPARING | 2003 |
|
RU2229879C1 |
AGENT "FORIDONE-GEL" FOR TREATMENT AND PROPHYLAXIS OF CARDIOVASCULAR DISEASES | 2004 |
|
RU2280438C2 |
THERAPEUTICAL AGENT "FORINIT-GEL" FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE | 2004 |
|
RU2277910C2 |
AGENT FOR TREATMENT OF DERMATOLOGICAL DISEASES | 2001 |
|
RU2197247C2 |
METHOD OF PREPARING GLYCOSIDE ELICITING CARDIOTONIC EFFECT | 1999 |
|
RU2196600C2 |
AGENT FOR TREATMENT OF SUPPURATIVE-NECROTIC PROCESSES | 1998 |
|
RU2145497C1 |
ANTI-INFLAMMATORY AND ANTIBACTERIAL DRUG FOR TOPICAL USE | 1998 |
|
RU2157214C2 |
DELAYED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING ASPARAGINATES | 2016 |
|
RU2632713C2 |
Authors
Dates
2002-01-20—Published
2000-06-20—Filed